Study to Monitor Subcutaneous Human Immunoglobulin Administered at Modified Dosing Regimens in Patients With Primary Immunodeficiency Diseases

NCT03939533 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

64

Enrollment

INDUSTRY

Sponsor class

Conditions

Primary Immune Deficiency Disorder

Interventions

DRUG: CUTAQUIG

Sponsor

Octapharma